Zhao-Ming Zhong1, Jian-Ting Chen. 1. Department of Orthopedic and Spinal Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, People's Republic of China.
Abstract
BACKGROUND AND OBJECTIVE: Male osteoporosis is an important public health issue and remains undertreated. We performed this meta-analysis to clarify the anti-fracture efficacy of risedronic acid in men. METHODS: Randomized controlled trials (RCTs) in men receiving risedronic acid or placebo published between 1980 and September 2008 were searched for in MEDLINE, EMBASE and the Cochrane Central Register of Controlled Trials. Studies with a follow-up of at least 12 months and providing the incidence of fractures were considered for inclusion in the review. Two independent reviewers assessed the methodological quality of the included studies and performed data extraction. Analysis of pooled data was carried out using Revman 4.2 software. RESULTS: Four RCTs met the inclusion criteria and permitted a pooled estimate of effectiveness. Relative risk with 95% confidence intervals for pooled effect under fixed effects model were: 0.31 (0.16, 0.60) for vertebral fractures and 0.40 (0.23, 0.70) for nonvertebral fractures, suggesting a 69% risk reduction of vertebral fractures and a 60% risk reduction of nonvertebral fracture with risedronic acid treatment in men. CONCLUSION: The results of this meta-analysis show that risedronic acid treatment is associated with a reduced risk of fractures in men.
BACKGROUND AND OBJECTIVE:Male osteoporosis is an important public health issue and remains undertreated. We performed this meta-analysis to clarify the anti-fracture efficacy of risedronic acid in men. METHODS: Randomized controlled trials (RCTs) in men receiving risedronic acid or placebo published between 1980 and September 2008 were searched for in MEDLINE, EMBASE and the Cochrane Central Register of Controlled Trials. Studies with a follow-up of at least 12 months and providing the incidence of fractures were considered for inclusion in the review. Two independent reviewers assessed the methodological quality of the included studies and performed data extraction. Analysis of pooled data was carried out using Revman 4.2 software. RESULTS: Four RCTs met the inclusion criteria and permitted a pooled estimate of effectiveness. Relative risk with 95% confidence intervals for pooled effect under fixed effects model were: 0.31 (0.16, 0.60) for vertebral fractures and 0.40 (0.23, 0.70) for nonvertebral fractures, suggesting a 69% risk reduction of vertebral fractures and a 60% risk reduction of nonvertebral fracture with risedronic acid treatment in men. CONCLUSION: The results of this meta-analysis show that risedronic acid treatment is associated with a reduced risk of fractures in men.
Authors: Adrianne C Feldstein; Gregory Nichols; Eric Orwoll; Patricia J Elmer; David H Smith; Michael Herson; Mikel Aickin Journal: Osteoporos Int Date: 2005-06-01 Impact factor: 4.507
Authors: Aliya A Khan; Anthony B Hodsman; Alexandra Papaioannou; David Kendler; Jacques P Brown; Wojciech P Olszynski Journal: CMAJ Date: 2007-01-30 Impact factor: 8.262
Authors: Cathleen S Colón-Emeric; Richard Lee; Carl F Pieper; Kenneth W Lyles; Leah L Zullig; Richard E Nelson; Katina Robinson; Ivuoma Igwe; Jyotsna Jadhav; Robert A Adler Journal: Contemp Clin Trials Date: 2021-11-27 Impact factor: 2.261
Authors: Margaret L Gourlay; Victor S Ritter; Jason P Fine; Robert A Overman; John T Schousboe; Peggy M Cawthon; Eric S Orwoll; Tuan V Nguyen; Nancy E Lane; Steven R Cummings; Deborah M Kado; Jodi A Lapidus; Susan J Diem; Kristine E Ensrud Journal: Arch Osteoporos Date: 2017-10-20 Impact factor: 2.617
Authors: Margaret L Gourlay; Robert A Overman; Jason P Fine; Guillaume Filteau; Peggy M Cawthon; John T Schousboe; Eric S Orwoll; Timothy J Wilt; Tuan V Nguyen; Nancy E Lane; Pawel Szulc; Brent C Taylor; Thuy-Tien Dam; Carrie M Nielson; Jane A Cauley; Elizabeth Barrett-Connor; Howard A Fink; Jodi A Lapidus; Deborah M Kado; Susan J Diem; Kristine E Ensrud Journal: Am J Prev Med Date: 2016-01-25 Impact factor: 5.043